文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

射血分数降低的心力衰竭

Heart failure with reduced ejection fraction.
PubMed 文献 · Lancet · 2025-11-27

本文综述射血分数降低的心力衰竭(HFrEF)的诊断与药物治疗现状。HFrEF约占全部心力衰竭病例的一半,现行指南导向药物治疗显著改善生存与生活质量,强调四类基础药物早期启动与快速上调滴定,并联合利尿剂缓解容量负荷症状。尽管治疗进展,心力衰竭仍是心血管疾病发病和死亡的主要原因之一,部分源于药物未实施和依从性差。

要点

  • HFrEF约占全部心力衰竭病例的一半,诊断依赖典型症状体征、利钠肽升高及心脏影像学结构或功能异常证据。
  • 现行指南导向药物治疗包括肾素-血管紧张素系统抑制剂或血管紧张素受体-脑啡肽酶抑制剂、β受体阻滞剂、盐皮质激素受体拮抗剂和钠-葡萄糖共转运蛋白2抑制剂四类基础药物。
  • 当代管理强调四类基础药物早期启动与快速上调滴定,并联合利尿剂缓解容量负荷症状。

核心结论

  • 现行指南导向药物治疗已显著改善HFrEF患者的生存率和生活质量,但心力衰竭仍是心血管疾病发病和死亡的主要原因之一,部分源于药物未实施和依从性差。

研究设计与样本

  • 本文为综述(Seminar),概述HFrEF患者的当前诊断与药物治疗,并指出进展与剩余挑战。

主要发现

  • 约一半心力衰竭病例归因于左心室收缩功能降低,分类为射血分数降低的心力衰竭(HFrEF)。

关键数值与推荐

  • 准确诊断依赖典型症状体征、利钠肽浓度升高及心脏影像技术显示心脏结构或功能异常的证据。
  • 当代管理强调四类基础药物早期启动与快速上调滴定:肾素-血管紧张素系统抑制剂或血管紧张素受体-脑啡肽酶抑制剂、β受体阻滞剂、盐皮质激素受体拮抗剂和钠-葡萄糖共转运蛋白2抑制剂,并联合利尿剂缓解容量负荷症状。
  • 未来改善结局的方向包括整合个性化医学方法、多组学分析和创新临床试验设计,以处理残余风险并识别新治疗靶点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in Europe and North America and approximately 1% in Asia and South America. Accurate diagnosis relies on the presence of typical signs and symptoms, elevated natriuretic peptide concentrations, and evidence of cardiac structural or functional abnormalities using cardiac imaging techniques. Approximately half of all heart failure cases are attributed to reduced left ventricular systolic function-classified as heart failure with reduced ejection fraction (HFrEF). Current guideline-directed medical therapy has markedly improved survival and quality of life for patients with HFrEF. Contemporary management emphasises early initiation and rapid uptitration of four foundational drug classes-renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors, β blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors-alongside diuretics for the symptom relief of volume overload. Despite advances in management, heart failure remains a leading cause of cardiovascular morbidity and mortality, partly due to absence of implementation of, and poor adherence to, medications. Future directions to improve outcomes include the integration of personalised medicine approaches, multiomic profiling, and innovative clinical trial designs to address residual risk and identify novel therapeutic targets. This Seminar provides an overview of the current diagnostic and pharmacological management of patients with HFrEF, highlighting the progress and outlining the challenges that remain.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Cannata A, Crespo-Leiro MG, Bromage DI, et al. Heart failure with reduced ejection fraction. Lancet. 2025. PMID: 41319669. doi:10.1016/S0140-6736(25)01851-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。